Alzheimer’s Society backs drug companies against NICE ruling

Posted on January 1st, by editor in Caring Times. No Comments

Two drug companies – Eisai Ltd, the licence holder of anti-dementia drug Aricept and Pfizer Ltd, Eisai’s co-promotion partner, have applied to the High Court for permission to request a Judicial Review of the process by which the National Institute for Health and Clinical Excellence (NICE) reached its decision to ban anti dementia medicines for NHS patients with newly diagnosed mild Alzheimer’s disease. The drug companies will be supported by other other parties, notably the Alzheimer’s Society, as co-claimants. Eisai wrote to NICE in November calling on the body to withdraw its Final Appraisal Document (FAD) and disclose a fully transparent working version of the model used in the calculation of cost-effectiveness and develop a new FAD using rational clinical assumptions and also to prevent discrimination against certain vulnerable groups of patients. NICE has refused to make any changes to the FAD or to disclose the requested model. As a result Eisai and Pfizer, have now applied for permission to pr

Comments are closed.

Latest blog posts

Time for a ten dollar answer

By Caring Times editor GEOFF HODGSON

Ernest Hemingway was known for his minimalist style and he used to pooh-pooh what he called “ten-dollar” words. Not to...

Lacking capacity

By guest blogger JEF SMITH

A friend of mine diagnosed with cancer – now, happily, treated – was asked how he could possibly have missed the...

Care homes – understated examples of tasteful design

By Caring Times editor GEOFF HODGSON

Dozens of recently-built care homes are material proof that it is perfectly possible to design aesthetically pleasing buildings and put...